

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
5 February 2004 (05.02.2004)

PCT

(10) International Publication Number
WO 2004/011433 A1

(51) International Patent Classification⁷: **C07D 211/86**

(21) International Application Number:
PCT/KR2003/001523

(22) International Filing Date: 30 July 2003 (30.07.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
10-2002-0044859 30 July 2002 (30.07.2002) KR

(71) Applicant (for all designated States except US): **CJ CORP.** [KR/KR]; 500, Namdaemunno 5-ga, Jung-gu, Seoul 100-802 (KR).

(71) Applicants and

(72) Inventors: **CHO, Seong-Hwan** [KR/KR]; #721-602, Hyundai Apt, 989-2 Yeongtong-dong, Paldal-gu, Suwon-si, Gyeonggi-do 422-470 (KR). **YOUN, Yong-Sik** [KR/KR]; #107-805, Poonglim Apt, 664 poongdukcheon-ri, Suji-eup, Yongin-si, Gyeonggi-do 449-846 (KR). **JUNG, Yun-Taek** [KR/KR]; #102-902, Halla Apt, Dorim-dong, Yeongdeungpo-gu, Seoul 150-080 (KR). **PARK, Choong-Sil** [KR/KR]; #D-203, Heights Villa, Ocheon-ri, Majang-myeon, Icheon-si, Gyeonggi-do 467-814 (KR). **LEE, Hyuk-Koo** [KR/KR]; #101-902, Life Apt, Mapyeong-dong, Yongin-si, Gyeonggi-do 449-040 (KR). **LEE, Kwang-Hyeg** [KR/KR]; #702-402, Mockryunmaul Hwaseong-village, Yatap-dong, Bundang-gu, Seongnam-si, Gyeonggi-do 463-070 (KR). **JEONG, Eun-Ju** [KR/KR]; #101-1102, Mockhwa Apt, 414 GwangHyewon-ri, manseung-myeon, Jinchon-gun, Chungcheongbuk-do 365-830 (KR). **KIM, Young-Hoon** [KR/KR]; #108-309, Hyundai Apt, Sillim 2-dong, Gwanak-gu, Seoul 151-761 (KR). **JIN, Hae-Tak** [KR/KR]; #105-1406, Hyundai Apt, 4-2 Gimryang-jang-dong, Yongin-si, Gyeonggi-do 449-709 (KR).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **CHEON, Jun-Hee** [KR/KR]; #149-904, Hwanggolmaul, 2 Yeongtong-dong,

Paldal-gu, Suwon-si, Gyeonggi-do 422-739 (KR). **LEE, Sung-Hak** [KR/KR]; #103-1004, Hyundai Apt, 700-1 Suji-eup, Yongin-si, Gyeonggi-do 449-840 (KR). **JUNG, Sung-Hak** [KR/KR]; #47-402, Joogong Apt, Gaepo 1-dong, Gangnam-gu, Seoul 135-966 (KR). **LIM, Dong-Kwon** [KR/KR]; #201-1804, Ccachimaul, Gumi-dong, Bundang-gu, Seongnam-si, Gyeonggi-do 463-500 (KR). **YEON, Kyo-Jeong** [KR/KR]; #126-801, Yeonwonmaul Samhobyeksan Apt., 524-8, mabuk-ri, Guseong-eup, Yongin-si, Gyeonggi-do 449-912 (KR). **KIM, Yun-Cheul** [KR/KR]; # 202, 368-2 Bulkwang 3-dong, Eunpyeong-gu, Seoul 122-043 (KR). **PARK, Kyung-Mi** [KR/KR]; #110-506, Hangang Hyundai Apt, Heukseok-dong, Dongjak-gu, Seoul 156-070 (KR). **KANG, Hyun-Suk** [KR/KR]; #102-1307, Seocho Hyundai Apt, Seocho 1-dong, Seocho-gu, Seoul 137-071 (KR).

(74) Agent: **SON, Min**; 17th Floor, City Air Tower, 159-9 Samsung-dong, Gangnam-gu, Seoul 135-973 (KR).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: ORGANIC ACID SALT OF AMLODIPINE

(57) Abstract: Disclosed are a novel organic salt of amlodipine, its preparation method, and a pharmaceutical composition containing the same as a therapeutically active ingredient.




WO 2004/011433 A1

ORGANIC ACID SALT OF AMLODIPINETechnical Field

The present invention relates to a novel organic acid salt of amlodipine (2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylic acid 3-ethyl 5-methyl ester), represented by the following chemical formula 1, its preparation method, and a pharmaceutical composition containing the same as an effective ingredient.

[Chemical Formula 1]

Background Art

10

With activity to block calcium channels in the body, amlodipine is used for the treatment of hypertension. This calcium channel blocker is found in many prior arts.

European Pat. Laid-Open Publication No. 89,167 discloses acid salts of amlodipine which can be formed from acids which may form nontoxic acid addition salts with

pharmaceutically acceptable anions, such as hydrochloride, hydrobromide, sulfate, phosphate, acetate, maleate, fumarate, lactate, tartrate, citrate, gluconate, etc.

U. S. Pat. No. 6,291,490 introduces a pharmaceutical composition containing as an active ingredient S-(-)-amlodipine which possesses potent activity in treating both systolic and diastolic hypertension while avoiding adverse effects associated with administration of the racemic mixture of amlodipine.

Both U. S. Pat. No. 4,879,303 and Korean Pat. Laid-Open Publication No. 1989-3375 disclose amlodipine besylate, saying that amlodipine besylate is superior over other salts of amlodipine, such as hydrochloride, acetate and mesylate in physicochemical properties including (1) solubility, (2) stability, (3) non-hygroscopicity, and (4) processability for tablet formulation.

However, since amlodipine besylate in current use has relatively low in solubility at pH 1-7.4, there is a need for novel salts which are of sufficient solubility, so as to increase the bioavailability of amlodipine and easily formulate its injections. Additionally, amlodipine besylate is found to be sensitive to light, so that decomposition products are observed when the salt is exposed to light.

Disclosure of the Invention

Leading to the present invention, the intensive and thorough research into therapeutically effective organic acid salts of amlodipine, conducted by the present inventors aiming to overcome the problems encountered in prior arts, resulted in the finding that amlodipine p-hydroxyphenylacetate has excellent physicochemical properties including solubility, non-hygroscopicity, chemical and light stability, and processability for dosage

formation.

Therefore, it is an object of the present invention to provide a p-hydroxyphenylacetic acid salt of amlodipine.

5 It is another object of the present invention to provide a method for preparing a p-hydroxyphenylacetic acid salt of amlodipine.

It is a further object of the present invention to provide a pharmaceutical composition containing the p-hydroxyphenylacetic acid salt of amlodipine as a therapeutically active ingredient.

10 In accordance with an aspect of the present invention, there is provided a p-hydroxyphenylacetic acid salt of amlodipine, preferably a light-stable p-hydroxyphenylacetic acid salt of amlodipine, and more preferably a crystalline p-hydroxyphenylacetic acid salt of amlodipine.

15 In accordance with another aspect of the present invention, there is provided a method for preparing a p-hydroxyphenylacetate acid salt of amlodipine, in which p-hydroxyphenylacetic acid is reacted with amlodipine in an inert solvent.


20 In accordance with a further aspect of the present invention, there is provided a pharmaceutical composition effective for the treatment of ischemic cardiac disorders or hypertension, comprising a therapeutically effective amount of amlodipine p-hydroxyphenylacetate and a pharmaceutically acceptable diluent or carrier preferably in the dosage form of tablets, capsules, solutions or injectables.

Best Mode for Carrying Out the Invention

The present invention encompasses amlodipine p-hydroxyphenylacetate,

represented by the following chemical formula 2.

[Chemical Formula 2]



5 Compared to amlodipine besylate in a commercially acceptable form, amlodipine p-hydroxyphenylacetate exhibits equal to or better non-hygroscopicity, formulation processability and chemical stability and especially, substantially increased solubility in distilled water or under various pH conditions. Moreover, an extraordinary improvement in stability to light is found in the p-hydroxyphenylacetate over other known organic acid salts, so that it can be stably stored for a long period of time without losing its medicinal effect as an anti-hypertensive agent. With feasibility of being formulated into solutions and injectables as well as difficulty of being precipitated in blood, the amlodipine p-hydroxyphenylacetate of the present invention is of great bioavailability.

1.0

The present invention also encompasses light-stable amlodipine p-hydroxyphenylacetate. The term "light-stable" as used herein means that after the salt is stored for 4 weeks at 25 °C with exposure to sunlight, its mass is maintained at 90 % or more of the original mass, preferably at 95 % or more, and more preferably at 98 % or more.


1.5

p-Hydroxyphenylacetic acid salts of amlodipine according to the present invention

may be in a crystal form or an amorphous form with preference to a crystal form.

The present invention also encompasses a method for preparing p-hydroxyphenylacetic acid salts of amlodipine. The salts can be prepared by reacting amlodipine with p-hydroxyphenylacetic acid in an inert solvent, as seen in the following
5 reaction formula 1.

[Reaction Formula 1]



Examples of the inert solvent suitable for the preparation of the salts of the present invention include ethyl acetate, methanol, ethanol, isopropanol, acetonitrile, hexane, isopropyl
10 ether and etc., with preference to methanol.

In the inert solvent, p-hydroxyphenylacetic acid is used in the amount of 1-2 equivalents and preferably in the amount of 1.02-1.2 equivalents per equivalent of amlodipine. The reaction is performed at -5 to 30 °C and preferably at 0 to 15 °C for 0.5 to 5 hours and preferably for 1 to 2 hours.

15 According to the method of the present invention, amlodipine p-hydroxyphenylacetate can be prepared at a yield of 90 % or higher.

Also, the present invention encompasses a pharmaceutical composition effective in treating both ischemic cardiac disorders or hypertension, which comprises a therapeutically effective amount of amlodipine p-hydroxyphenylacetate and a pharmaceutically acceptable

diluent or carrier.

The composition of the present invention may be formulated into oral dosage forms including, but not limited to, granules, powders, solutions, tablets, capsules, dry syrup and the like, or parenteral dosage forms including injectables. The composition of the present invention is preferably formulated in the dosage form of tablets, capsules, solutions or injectables.

To be therapeutically effective, amlodipine p-hydroxyphenylacetate is administered at a dose of 2-10 mg per day on the basis of the weight of amlodipine. In a unit dosage form, amlodipine p-hydroxyphenylacetate is contained in the amount of 2.8-13.8 mg.

In practical use, amlodipine p-hydroxyphenylacetate can be combined as the active ingredient in admixture with a pharmaceutically acceptable diluent or carrier selected from among excipients, disintegrants, binders, lubricants and mixtures thereof. The carrier may take a wide variety of forms depending on the form of the preparation desired for administration. In preparing the composition in a solid dosage form such as a tablet or a hard capsule, there may be employed microcrystalline cellulose, lactose, low-substituted hydroxycellulose and the like as an excipient; sodium starch glycollate, anhydrous potassium monohydrogenphosphate and the like as a disintegrant; polyvinylpyrrolidone, low-substituted hydroxypropylcellulose, hydroxypropylcellulose and the like as a binder; and magnesium stearate, silica, talc and the like as a lubricant.

A formulation may comprise an additive to provide sheen to the tablet such as anhydrous dibasic calcium phosphate. To prevent atmospheric moisture from penetrating into the tablet, it may be coated with a water-insoluble material. The coating base must have a dense molecular structure and is preferably poorly soluble in water. Suitable for the base is a polymeric material selected from among methacrylic acid copolymer, hydroxypropylmethyl

cellulose phthalate, cellulose acetate phthalate, hydroxypropylmethylcellulose acetate succinate, polyvinyl alcohol and combinations thereof. Also, the coating may comprise conventional additives such as plasticizers, preservatives, coloring agents, light shielders, etc.

The composition of the present invention may be in the form of solutions such as sterile aqueous solution, or injectables. Such solution contains, if necessary, from 10 to 40% of propylene glycol and sodium chloride sufficient to avoid hemolysis (e.g. about 1%).

A better understanding of the present invention may be obtained in light of the following examples which are set forth to illustrate, but are not to be construed to limit the present invention.

10 EXAMPLES

Amlodipine p-hydroxyphenylacetate prepared according to the present invention was tested for various physical properties. First, the salt was formulated into tablets, capsules and aqueous solutions to test the processability for dosage formation. Also, amlodipine p-hydroxyphenylacetate was compared with known salts of amlodipine with regard to hygroscopicity, solubility, stability and light stability.

In the following reference examples, conventional salts of amlodipine were prepared according to methods disclosed in the art.

REFERENCE EXAMPLE 1: Preparation of Amlodipine Besylate.

Amlodipine was prepared as disclosed in Korean Pat. Publication No. 87-809. The method described in Korean Pat. Publication No. 95-7228 was adopted to produce amlodipine

besylate.

REFERENCE EXAMPLE 2: Preparation of Amlodipine para-toluenesulfonate

In 100 ml of methanol was dissolved 20 g of para-toluenesulfonic acid. To the solution, 40 g of the amlodipine prepared in Reference Example 1 in 500 ml of methanol was added dropwise, followed by stirring at 23 °C for 3 hours.

After being filtered off, the solid thus produced was washed with 100 ml of methanol and 100 ml of n-hexane and dried in vacuo.

REFERENCE EXAMPLE 3: Preparation of Amlodipine hydrochloride

To 100 ml of methanol was added 12 ml of conc-hydrochloric acid. 54 g of amlodipine prepared in Reference Example 1 in 500 ml of methanol was added dropwise, followed by stirring at 23 °C for 3 hours.

After being filtered off, the solid thus obtained was washed with 100 ml of methanol and 100 ml of n-hexane and dried in vacuo.

EXAMPLE 1: Preparation of Amlodipine p-hydroxyphenylacetate

Into an Erlenmyer flask were poured p-hydroxyphenylacetic acid (1.52 g) and ethylacetate (50 ml). Into the flask was dropwise added a solution of amlodipine (4.0g) in ethylacetate (100 ml), followed by stirring the solution at 23 °C for 3 hours to give precipitates. After being filtered off, the precipitates were washed with ethylacetate (50 ml)

and then with hexane (50 ml) and dried at 23 °C under vacuum to allow 5.1 g of amlodipine p-hydroxyphenylacetate as a crystalline solid (Yield 92%).

The element analysis and melting point of the amlodipine p-hydroxyphenylacetate prepared above were determined.

5

TABLE 1

	Element analysis for C ₂₄ H ₃₃ CIN ₂ O ₈ (unit %)			
Found	C : 55.9	H : 5.9	N : 5.0	O : 20.8
Calculated	C : 59.5	H : 6.0	N : 4.9	O : 22.8

Melting point: 160 °C

(measured by capillary melting point method with heating rate of about 1 °C/minute)

EXAMPLE 2: Formulation of Tablet Containing Amlodipine p-hydroxyphenylacetate

10

The ingredients given in Table 2 were formulated to prepare a tablet containing amlodipine p-hydroxyphenylacetate.

TABLE 2

Ingredients	Contents (mg per tablet)
Amlodipine p-hydroxyphenylacetate	5.0 based on Amlodipine
Low-substituted Hydroxypropylcellulose	65
Microcrystalline Cellulose	120
Sodium Starch Glycollate	4
Magnesium Stearate	2

The ingredients were blended and the blend was compressed using a roller press from Jwoon Machinery, and then the compressed material was formulated into tablets using a tableting machine from Erweka.

EXAMPLE 3: Formulation of Tablet Containing Amlodipine p-hydroxyphenylacetate

The ingredients given in Table 3 were formulated to prepare a tablet containing amlodipine p-hydroxyphenylacetate.

TABLE 3

Ingredients	Contents (mg per tablet)
Amlodipine p-hydroxyphenylacetate	5.0 based on Amlodipine
Lactose	180
Cross Povidone	6
Polyvinylpyrrolidone K90	6
Sodium Starch Glycollate	4
Magnesium Stearate	2

5 Lactose, cross povidone and polyvinylpyrrolidone K90 were preblended. The preblend was granulated according to a fluidized bed assembly method (SPIRA FLOW) and the granules were blended with the remaining ingredients and formulated into tablets using a tablet machine from Erweka.

EXAMPLE 4: Formulation of Capsule Containing Amlodipine p-hydroxyphenylacetate

10 The ingredients given in Table 4 were formulated to prepare a capsule containing amlodipine p-hydroxyphenylacetate.

TABLE 4

Ingredients	Contents (mg per capsule)
Amlodipine p-hydroxyphenylacetate	5.0 based on Amlodipine

Low-substituted Hydroxypropylcellulose	65
Microcrystalline Cellulose	120
Sodium Starch Glycollate	4
Magnesium Stearate	2

The ingredients were blended and the blend was compressed using a roller press from Jowoon Machinery, and then the compressed material was filled into hard gelatin capsules using a capsule filling device from Bosche.

EXAMPLE 5: Formulation of Capsule Containing Amlodipine p-hydroxyphenylacetate

5 The ingredients given in Table 5 were formulated to prepare a capsule containing amlodipine p-hydroxyphenylacetate.

TABLE 5

Ingredients	Contents (mg per capsule)
Amlodipine p-hydroxyphenylacetate	5.0 based on Amlodipine
Lactose	180
Cross Povidone	6
Polyvinylpyrrolidone K90	6
Sodium Starch Glycollate	4
Magnesium Stearate	2

Lactose, cross povidone and polyvinylpyrrolidone K90 were preblended. The pre-blend was granulated according to a fluidized bed assembly method (SPIRA FLOW) and the
 10 granules were blended with the remaining ingredients and filled in hard gelatin capsules using a capsule filling machine from Bosche.

EXAMPLE 6: Test for Hygroscopicity of Amlodipine p-hydroxyphenylacetate

Amlodipine p-hydroxyphenylacetate prepared in Example 1 and amlodipine besylate prepared in Reference Example 1 were tested for hygroscopicity by measuring their water contents (K.F. water%) at 25 °C at different humidity levels. The results are given in Table 6, below.

5

TABLE 6

Humidity Conditions (RH)		25%	60%	75%	90%
Storage Period (week)	Initial	1	1	1	1
p-hydroxyphenylacetate(%)	0.15	0.08	0.1	0.14	0.17
Besylate (%)	0.14	0.10	0.09	0.15	0.17

As shown in Table 6, the non-hygroscopicity of amlodipine p-hydroxyphenylacetate is equal to or better than that of amlodipine besylate. With a hygroscopicity of 0.5% or less at relative humidity 95%, the salt is suitable for the formulation of tablets, capsules, injectables, and the like.

10

EXAMPLE 7: Test for Solubility of Amlodipine p-hydroxyphenylacetate

Solubilities of amlodipine p-hydroxyphenylacetate prepared in Example 1 and amlodipine besylate prepared in Reference Example 1 in various solvents were measured at 25 °C. The results are given in Table 7, below. The solubilities (mg/ml) of Table 6 are values based on the weight of amlodipine converted from the salts.

15

TABLE 7

Solvents	Salts (mg/ml)		Note
	p-Hydroxyphenylacetate	Besylate	

Dist. Water	3.0	1.29	Ionic Strength 0.2 buffer Dissolved at 37°C
pH 2	8.9	1.29	
pH 4	8.8	1.32	
pH 6	2.2	1.28	
pH 7	1.1	0.64	
pH 7.4	4.0	1.35	
pH 8	3.0	1.25	

As seen in Table 7, solubilities of amlodipine p-hydroxyphenylacetate in distilled water and buffers of various pH are much higher than those of amlodipine besylate. That is, amlodipine ethanesulfonate shows far superior solubility properties to amlodipine besylate.

EXAMPLE 8: Test for Stability of Amlodipine p-hydroxyphenylacetate

5 1. Chemical stability of amlodipine p-hydroxyphenylacetate in solid state

Amlodipine p-hydroxyphenylacetate prepared in Example 1 and amlodipine besylate prepared in Reference Example 1 were subjected to an accelerated test at 60 °C and the results are summarized in Table 8, below.

TABLE 8

Salts	Storage Period			
	initial	1 week	2 weeks	4 weeks
PyroGlu	99.7%	99.6%	99.5%	99.4%
Besylate	99.6%	99.6%	99.4%	99.2%

10

(unit HPLC content %)

HPLC Analysis Conditions:

Detector: UV Absorbance (at 237 nm)

Column: Octadecyl silica gel C18 (4.6mmx150mm,5 µm)

Mobile Phase: Potassium dihydrogenphosphate monobasic (0.03M): methanol=4:6

(v/v)

Flow Rate: 1.5 ml/min

As shown in Table 8, there were virtually no changes in the content of amlodipine p-hydroxyphenylacetate, like amlodipine besylate, as measured by accelerated test at 60 °C.

5 The data of Table 8 demonstrate that, comparable to that of amlodipine besylate, the chemical stability of amlodipine p-hydroxyphenylacetate is excellent.

2. Chemical stability of amlodipine p-hydroxyphenylacetate in aqueous state

To investigate the stability in aqueous state, amlodipine p-hydroxyphenylacetate prepared in Example 1 and amlodipine besylate prepared in Reference Example 1 were
10 separately dissolved in distilled water. The resulting aqueous solutions were stored at 25 °C for 4 weeks in complete darkness, after which a measurement was made of the contents of the salts with resort to HPLC under the same conditions as in the solid state.

The results of the light-shielded stability test indicate that neither decomposition products nor content change is found in both amlodipine p-hydroxyphenylacetate and
15 amlodipine besylate.

EXAMPLE 9: Test for light Stability of Amlodipine p-hydroxyphenylacetate

Amlodipine p-hydroxyphenylacetate prepared in Example 1, and amlodipine besylate and other salts of amlodipine prepared in Reference Example 1 to 3 were separately
20 dissolved in distilled water. The resulting aqueous solutions were stored at 25 °C for 4 weeks while being exposed to sunlight. A measurement was made of the contents of the salts with resort to HPLC under the same conditions as in the chemical stability test. The

results are given in Table 9, below.

TABLE 9

Salts	Initial	Stored for 4 weeks, 25°C sunlight
	Content (HPLC)	Content (HPLC)
p-Hydroxyphenylacetate	99.5%	98.9%
Besylate	99.2%	82.5%
Tosylate	99.2%	72.0%
Hydrochloride	99.0%	60.5%

As apparent from Table 9, a smaller reduction in content was found in amlodipine p-hydroxyphenylacetate than in the other salts of amlodipine. It was also found that amlodipine besylate turned yellow from white while amlodipine p-hydroxyphenylacetate kept its original white color. These data accordingly show that amlodipine p-hydroxyphenylacetate is superior in light stability to amlodipine besylate. This is very important for anti-hypertensives that are administered to the patients for a long period of time.

Industrial Applicability

Taken together, the data presented in the above examples indicate that the amlodipine p-hydroxyphenylacetate of the present invention has excellent physicochemical properties including hygroscopicity, chemical and light stability, solubility and processability for dosage formulation, and is easy to deliver in the body of a patient and stored for a long period of time with its superior solubility and stability.

What is Claimed Is:

1. A p-hydroxyphenylacetic acid salt of amlodipine.

2. The p-hydroxyphenylacetic acid salt of amlodipine as defined in claim 1, wherein the salt is in crystalline form.

5 3. A method for preparing a p-hydroxyphenylacetic acid salt of amlodipine, comprising the step of reacting amlodipine with p-hydroxyphenylacetic acid in an inert solvent.

 4. A pharmaceutical composition for the treatment of ischemic cardiac disorders or hypertension, comprising a therapeutically effective amount of the p-hydroxyphenylacetic acid salt of claim 1 or 2, and a pharmaceutically acceptable diluent or carrier.
10

5. The pharmaceutical composition as defined in claim 4, wherein the composition is in the form of tablets or capsules.

6. The pharmaceutical composition as defined in claim 4, wherein the composition is in the form of solutions or injectables.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/KR03/01523

A. CLASSIFICATION OF SUBJECT MATTER

IPC7 C07D 211/86

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7 C07D 211/86

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Korean Patents and applications for inventions since 1975
Japanese Patents and applications for inventions since 1975

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CAPLUS(STN), MEDILINE(STN), USPATFULL, NPS, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 244944 A2 (PFIZER LIMITED) 31 MAR. 1987 SEE THE WHOLE DOCUMENT	1 - 6
A	US 4572909 A (PFIZER INC.) 25 FEB. 1986 SEE THE WHOLE DOCUMENT	1 - 6
A	US 6057344 A (SEPRACOR INC.) 02 MAY. 2000 SEE COL. 11 (LINE 1 - LINE 9)	1 - 6
A	US 480657 A (PFIZER INC.) 21 FEB. 1989 SEE COL. 3 (LINE 50 - LINE 57)	1 - 6
A, P	KR 1020020076561 A (HANMI PHARMACEUTICAL CO.) 11 OCT. 2002 SEE THE WHOLE DOCUMENT	1 - 6

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family


Date of the actual completion of the international search

21 OCTOBER 2003 (21.10.2003)

Date of mailing of the international search report

21 OCTOBER 2003 (21.10.2003)

Name and mailing address of the ISA/KR

 Korean Intellectual Property Office
920 Dunsan-dong, Seo-gu, Daejeon 302-701,
Republic of Korea

Facsimile No. 82-42-472-7140

Authorized officer

KANG, Choon Won

Telephone No. 82-42-481-5608



INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/KR03/01523

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0244944 A2	07.11.1989	AP50A	16.09.1989
		CA1321393C	17.08.1993
		DD265142A5	22.02.1989
		DE3710457A1	08.10.1987
		DE3761485D1	01.03.1990
		DK170187A	05.10.1987
		EG18266A	30.12.1992
		EPO244944A2	11.11.1987
		ES2002599A6	16.08.1988
		F1871470A	05.10.1987
		FR2596758A1	09.10.1987
		GR870525A1	12.08.1987
		HU43821A2	28.12.1987
		IE59457B1	23.02.1994
		IL82101A	31.01.1991
		IN168414A1	30.03.1991
		IT1203853B	23.02.1989
JP62240660A	21.10.1987		
KR9506710B1	21.06.1995		
US4572909A	25.02.1986	AU1235183A	22.09.1983
		CA1253865A1	09.05.1989
		CS9104188A3	16.09.1992
		DD218887A5	20.02.1985
		DE3366920D1	20.11.1986
		DK81383A	12.09.1983
		EG16987A	30.03.1991
		EPO089167A2	21.09.1983
		ES8503654A1	16.06.1985
		ES8505201A1	16.08.1985
		F1830789A	12.09.1983
		GR77429A1	14.09.1984
		HK16288A	11.03.1988
		HU187868B	28.02.1986
		IE54667B1	03.01.1990
		IL68091A	30.11.1986
		JP58167569A	03.10.1983
		KR8700809B1	20.04.1987
		LU88332A9	04.05.1994
		NO830847A	12.09.1983
		NZ203521A	13.09.1985
PL240854A1	09.04.1985		
PL250767A1	17.12.1985		
PT76370A	01.04.1983		
SG98687G	23.09.1988		
US6057344A	02.05.2000	NONE	
US4806557A	21.02.1989	NONE	
KR1020020076561A	11.10.2002	NONE	